Relay Therapeutics (RLAY) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.41
- EPS estimate
- −$0.39
- EPS surprise
- −4.83%
- Revenue surprise
- −63.54%
- Revenue
- $350,000.00
- Revenue estimate
- $960,000.00
- Reported
- Aug 6, 2026
Relay Therapeutics reported Q2 2026 results on August 6, 2026. The company posted a loss of $0.41 per share, slightly wider than the expected loss of $0.39, a miss of 4.83%. Revenue was $350,000, against an estimate of $960,000. The loss per share matched Q2 2025, while revenue was half of that quarter's $700,000.
Every quarter in the table is a loss. The annual loss per share was $2.60 in 2022 and $2.80 in 2023, then narrowed to $2.39 in 2024 and $1.62 in 2025. The smallest quarterly loss was $0.32 in Q4 2025 and the largest was $0.81 in Q2 2023. Revenue is small and irregular. Five of the last 20 quarters show no revenue figure, and the largest amount in the table was $25.2 million in Q3 2023. Relay beat the EPS estimate in 12 of the last 20 quarters, but in only one of the last four.
Relay reported its third quarter between November 2 and November 10 in each of the past five years. That points to early November 2026 for the next report. It will show whether the quarterly loss stays around the $0.41 per share of the last two quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.39 | −$0.41 | −4.83% | $350,000.00 | SEC |
| Q1 2026 | May 5, 2026 | −$0.36 | −$0.41 | −12.89% | $3.0M | SEC |
| Q4 2025 | Feb 26, 2026 | −$0.40 | −$0.32 | +20.91% | $7.0M | SEC |
| Q3 2025 | Nov 6, 2025 | −$0.42 | −$0.43 | −3.54% | $0.00 | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.49 | −$0.41 | +16.63% | $700,000.00 | SEC |
| Q1 2025 | May 5, 2025 | −$0.49 | −$0.46 | +5.99% | $7.7M | SEC |
| Q4 2024 | Feb 26, 2025 | −$0.56 | −$0.45 | +19.81% | $0.00 | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.77 | −$0.63 | +18.38% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.73 | −$0.69 | +5.83% | $0.00 | SEC |
| Q1 2024 | May 2, 2024 | −$0.73 | −$0.62 | +14.69% | $10.0M | SEC |
| Q4 2023 | Feb 22, 2024 | −$0.72 | −$0.67 | +6.71% | −$4,000.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.83 | −$0.54 | +34.55% | $25.2M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.82 | −$0.81 | +0.67% | $119,000.00 | SEC |
| Q1 2023 | May 4, 2023 | −$0.69 | −$0.78 | −12.85% | $226,000.00 | SEC |
| Q4 2022 | Feb 23, 2023 | −$0.70 | −$0.56 | +20.25% | $253,000.00 | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.71 | −$0.76 | −7.71% | $344,000.00 | SEC |
| Q2 2022 | Aug 4, 2022 | −$0.63 | −$0.71 | −13.22% | $365,000.00 | SEC |
| Q1 2022 | May 5, 2022 | −$0.62 | −$0.57 | +7.81% | $419,000.00 | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.56 | −$0.59 | −5.56% | $567,000.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.61 | −$0.66 | −7.84% | $666,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Relay Therapeutics (RLAY) last report earnings?
Relay Therapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did RLAY beat earnings estimates?
No. Relay Therapeutics reported EPS of −$0.41 for Q2 2026 against a −$0.39 estimate — a 4.83% miss.
How much revenue did RLAY report last quarter?
Relay Therapeutics reported $350,000.00 in revenue for Q2 2026, against a consensus estimate of $960,000.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.